HinokiolCAS# 564-73-8 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 564-73-8 | SDF | Download SDF |
PubChem ID | 12310492 | Appearance | Powder |
Formula | C20H30O2 | M.Wt | 302.5 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2S,4aS,10aR)-1,1,4a-trimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-2,6-diol | ||
SMILES | CC(C)C1=C(C=C2C(=C1)CCC3C2(CCC(C3(C)C)O)C)O | ||
Standard InChIKey | ODFCWXVQZAQDSO-CMKODMSKSA-N | ||
Standard InChI | InChI=1S/C20H30O2/c1-12(2)14-10-13-6-7-17-19(3,4)18(22)8-9-20(17,5)15(13)11-16(14)21/h10-12,17-18,21-22H,6-9H2,1-5H3/t17-,18-,20+/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Hinokiol demonstrates potent activity against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). 2. Hinokiol has significant inhibitory effects on 5-hydroxy-eicosa-tetra-enoic acid (5-HETE) and leukotriene B(4) (LTB4) formations, suggests that it has anti-inflammatory activity. |
Targets | LOX | NO | TNF-α | COX | Antifection |
Hinokiol Dilution Calculator
Hinokiol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3058 mL | 16.5289 mL | 33.0579 mL | 66.1157 mL | 82.6446 mL |
5 mM | 0.6612 mL | 3.3058 mL | 6.6116 mL | 13.2231 mL | 16.5289 mL |
10 mM | 0.3306 mL | 1.6529 mL | 3.3058 mL | 6.6116 mL | 8.2645 mL |
50 mM | 0.0661 mL | 0.3306 mL | 0.6612 mL | 1.3223 mL | 1.6529 mL |
100 mM | 0.0331 mL | 0.1653 mL | 0.3306 mL | 0.6612 mL | 0.8264 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 11α-Hydroxyandrost-4-ene-3,17-dione
Catalog No.:BCC8432
CAS No.:564-33-0
- Doxycycline
Catalog No.:BCN2397
CAS No.:564-25-0
- Sclareolide
Catalog No.:BCC6492
CAS No.:564-20-5
- Hop-17(21)-en-3-ol
Catalog No.:BCN5755
CAS No.:564-14-7
- UK-5099
Catalog No.:BCC2021
CAS No.:56396-35-1
- Metoprolol Tartrate
Catalog No.:BCC4330
CAS No.:56392-17-7
- Netilmicin Sulfate
Catalog No.:BCC4683
CAS No.:56391-57-2
- Epirubicin HCl
Catalog No.:BCC1192
CAS No.:56390-09-1
- Tirotundin
Catalog No.:BCN5754
CAS No.:56377-67-4
- Capillarisin
Catalog No.:BCN2461
CAS No.:56365-38-9
- Oxybutynin
Catalog No.:BCC3833
CAS No.:5633-20-5
- Hedychenone
Catalog No.:BCN5753
CAS No.:56324-54-0
- Tetrahydrolachnophyllum lactone
Catalog No.:BCN4759
CAS No.:56407-87-5
- Methyl eichlerianate
Catalog No.:BCN5756
CAS No.:56421-12-6
- Eichlerianic acid
Catalog No.:BCN5757
CAS No.:56421-13-7
- 4,9-Dihydroxy-alpha-lapachone
Catalog No.:BCN5758
CAS No.:56473-67-7
- Steppogenin
Catalog No.:BCN5760
CAS No.:56486-94-3
- Angelic acid
Catalog No.:BCN3410
CAS No.:565-63-9
- 2-Hydroxy-3,4-dimethoxybenzoic acid
Catalog No.:BCN6535
CAS No.:5653-46-3
- Cyclo(Tyr-Pro)
Catalog No.:BCN2421
CAS No.:5654-84-2
- Cyclo(Pro-Leu)
Catalog No.:BCN2426
CAS No.:5654-86-4
- Cyclo(Pro-Val)
Catalog No.:BCN2420
CAS No.:5654-87-5
- (-)-Bornyl acetate
Catalog No.:BCN2636
CAS No.:5655-61-8
- PIT
Catalog No.:BCC7151
CAS No.:56583-49-4
Antibacterial activity of Taxodium ascendens diterpenes against methicillin-resistant Staphylococcus aureus.[Pubmed:25233589]
Nat Prod Commun. 2014 Aug;9(8):1129-30.
One new and seven known diterpenes were identified from an antibacterial chromatographic fraction of Taxodium ascendens. Of these, demethylcryptojaponol (2), 6-hydroxysalvinolone (3), hydroxyferruginol (4), and Hinokiol (5) demonstrated potent activity against clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA). These compounds represent a class of synthetically accessible compounds that could be further developed for treatment of drug-resistant bacterial infections.
The anti-inflammatory activities of an extract and compounds isolated from Platycladus orientalis (Linnaeus) Franco in vitro and ex vivo.[Pubmed:21619922]
J Ethnopharmacol. 2012 Jun 1;141(2):647-52.
ETHNOPHARMACOLOGICAL RELEVANCE: As a Chinese traditional herbal medicine, leaves of Platycladus orientalis (Linnaeus) Franco (LPO) are used to treat coughs, excessive mucus secretion, chronic bronchitis, bronchiectasis, and asthma, etc. The experiments were carried out to investigate their anti-inflammatory properties and mechanisms, which could support the Chinese traditional uses of treating inflammatory airway diseases. MATERIALS AND METHODS: The anti-inflammatory activities of the chloroform fraction (CHL) and pure compounds of LPO were evaluated for their abilities to inhibit pro-inflammatory enzymes in vitro, and production of tumor necrosis factor-alpha (TNF-alpha) and nitric oxide in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. Furthermore, the arachidonic acid metabolites, stimulated by calcium ionophore A23187, were also determined by HPLC. RESULTS: For the first time, the assays of eicosanoids in intact cells showed that the CHL, Hinokiol, and acacetin had significant inhibitory effects on 5-hydroxy-eicosa-tetra-enoic acid (5-HETE) and leukotriene B(4) (LTB4) formations. And cell-free enzyme assays (5-lipoxygenase, leukotriene A(4)-hydrolase, cyclooxgenase-2) demonstrated the potent inhibitory effects of the CHL, Hinokiol and acacetin on 5-lipoxygenase (5-LOX). Then, the inhibitions of the CHL, Hinokiol on NO biosynthesis and the inhibitions of the CHL, 8(14),15-pimaradien-3beta,18-diol, and Hinokiol on TNF-alpha release were also confirmed in the RAW264.7 murine macrophages. CONCLUSION: The data indicate that the inhibitory effects of the CHL and its components (Hinokiol and acacetin) on 5-LOX contribute to the anti-inflammatory activity of LPO. Moreover, the CHL and its components also show beneficial effects on NO and TNF-alpha production. Consequently, these results provide a rationale for LPO's traditional applications in the treatment of inflammatory airway diseases.